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Abstract
Maize 4114 was developed through Agrobacterium tumefaciens-mediated transformation to provide
protection against certain lepidopteran and coleopteran pests by expression of the Cry1F, Cry34Ab1
and Cry35Ab1 proteins derived from Bacillus thuringiensis, and tolerance to the herbicidal active
ingredient glufosinate-ammonium by expression of the PAT protein derived from Streptomyces
viridochromogenes. The molecular characterisation data did not identify issues requiring assessment
for food/feed safety. None of the compositional, agronomic and phenotypic differences identiﬁed
between maize 4114 and the non-genetically modiﬁed (GM) comparator(s) required further
assessment. There were no concerns regarding the potential toxicity and allergenicity of the newly
expressed proteins Cry1F, Cry34Ab1, Cry35Ab1 and PAT, and no evidence that the genetic modiﬁcation
might signiﬁcantly change the overall allergenicity of maize 4114. The nutritional value of food/feed
derived from maize 4114 is not expected to differ from that derived from non-GM maize varieties and
no post-market monitoring of food/feed is considered necessary. In the case of accidental release of
viable maize 4114 grains into the environment, maize 4114 would not raise environmental safety
concerns. The post-market environmental monitoring plan and reporting intervals are in line with the
intended uses of maize 4114. The genetically modiﬁed organism (GMO) Panel concludes that
maize 4114 is as safe as the non-GM comparator(s) and non-GM reference varieties with respect to
potential effects on human and animal health and the environment in the context of the scope of this
application.
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Summary
Following the submission of the application EFSA-GMO-NL-2014-123 under Regulation (EC)
No 1829/2003 from Pioneer Overseas Corporation, the Panel on Genetically Modiﬁed Organisms of
the European Food Safety Authority (EFSA) (GMO Panel) was asked to deliver a Scientiﬁc Opinion on
the safety of genetically modiﬁed (GM) maize (Zea mays L.) 4114 (Unique Identiﬁer DP-ØØ4114-3).
The scope of the application EFSA-GMO-NL-2014-123 is for import, processing and food and feed
uses of maize 4114 within the European Union (EU), but excludes cultivation in the EU.
The GMO Panel evaluated maize 4114 with reference to the scope of the application and
appropriate principles described in its guidelines for the risk assessment of GM plants. The evaluation
addressed the following components of the risk assessment: the molecular characterisation of the
inserted DNA and analysis of the expression of the corresponding proteins; the comparative analyses
of compositional, agronomic and phenotypic characteristics; the safety of the newly expressed proteins
and of the whole food/feed with respect to potential toxicity, allergenicity, nutritional characteristics
and dietary exposure; the environmental risk assessment and the post-market environmental
monitoring (PMEM) plan.
Maize 4114 was developed through Agrobacterium tumefaciens-mediated transformation of
immature maize embryos of maize line PHWWE to express the Cry1F (truncated version), Cry34Ab1
and Cry35Ab1 proteins providing protection against speciﬁc lepidopteran and coleopteran pests, and
the PAT protein conferring tolerance to the herbicidal active ingredient glufosinate-ammonium. The
molecular characterisation data established that maize 4114 contains a single insert consisting of the
cry1F, cry34Ab1, cry35Ab1 and pat expression cassettes, and genetic stability was demonstrated. No
other parts of the plasmid used for transformation were detected in maize 4114. Bioinformatic
analyses did not indicate signiﬁcant similarities to toxins and allergens. The Cry1F, Cry34Ab1, Cry35Ab1
and PAT proteins were detected and quantiﬁed in different tissues.
The comparative assessment of agronomic and phenotypic characteristics did not identify
differences between maize 4114 and its non-GM comparator(s) requiring further assessment. There
were no concerns regarding the potential toxicity and allergenicity of the newly expressed proteins
Cry1F, Cry34Ab1 and Cry35Ab1 and PAT, and no evidence that the genetic modiﬁcation might
signiﬁcantly change the overall allergenicity of maize 4114. The nutritional value of food/feed derived
from maize 4114 is not expected to differ from that of food/feed derived from non-GM maize varieties
and no post-market monitoring of food/feed is considered necessary.
Considering the introduced traits, the outcome of the comparative analysis, the routes and levels of
exposure, the GMO Panel concludes that maize 4114 would not raise safety concerns in the event of
accidental release of viable GM maize grains into the environment. The PMEM plan and reporting
intervals are in line with the intended uses of maize 4114.
Based on the relevant scientiﬁc publications retrieved through systematic literature searches, the
GMO Panel did not identify any safety issues pertaining to the intended uses of maize 4114. In the
context of PMEM, the applicant should improve the literature searches according to the GMO
Panel recommendations.
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2014-
123, additional information provided by the applicant, scientiﬁc comments submitted by the Member
States and relevant scientiﬁc publications. The GMO Panel concludes that maize 4114, as described in
this application, is as safe as its non-GM comparator(s) and the tested non-GM reference varieties with
respect to potential effects on human and animal health and the environment.
Assessment of maize 4114
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1. Introduction
The scope of application EFSA-GMO-NL-2014-123 is for food and feed uses, import and processing
of maize 4114 and does not include cultivation in the European Union (EU).
Maize 4114 was developed to confer resistance against speciﬁc lepidopteran and coleopteran pests
by the expression of the cry1F, cry34Ab1 and cry35Ab1 genes derived from Bacillus thuringiensis (Bt)
and tolerance to the herbicidal active ingredient glufosinate-ammonium by expression of the PAT gene
derived from Streptomyces viridochromogenes.1
1.1. Background
On 27 November 2014, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands application EFSA-GMO-NL-2014-123 for authorisation of maize 4114
(Unique Identiﬁer DP-ØØ4114-3), submitted by Pioneer Overseas Corporation (hereafter referred as
the applicant) within the framework of Regulation (EC) No 1829/2003 on genetically modiﬁed (GM)
food and feed.2
After receiving the application EFSA-GMO-NL-2014-123, and in accordance with Articles 5(2)(b) and
17(2)(b) of Regulation (EC) No 1829/2003, EFSA informed the Member States and the European
Commission, and made the summary of the application available to the public on the EFSA website.3
EFSA initiated a formal review of the application to check compliance with the requirements laid down
in Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003 and Regulation (EU) No 503/20134.
EFSA requested additional information under completeness check on 20 January 2015 and received
it on 2 March 2015 and 24 April 2015. On 30 March 2015, EFSA declared the application valid in
accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003.
EFSA made the valid application available to Member States and the European Commission and
consulted nominated risk assessment bodies of Member States, including national Competent
Authorities within the meaning of Directive 2001/18/EC5 following the requirements of Articles 6(4)
and 18(4) of Regulation (EC) No 1829/2003 to request their scientiﬁc opinion. Member States had 3
months after the opening of the Member State commenting period (until 11 September 2015) to make
their opinion known.
The genetically modiﬁed organism (GMO) Panel requested additional information from the applicant
on 23 April 2015 (EURL-GMFF), 11 May 2015, 17 July 2015, 3 December 2015, 12 February 2016, 29
June 2016, 18 July 2016 (EURL-GMFF), 5 December 2016, 14 March 2017, 24 May 2017 and 25
September 2017. The applicant provided the requested information on 1 June 2016 (EURL-GMFF), 10
June 2016 (EURL-GMFF), 23 September 2015, 15 December 2015, 12 April 2016, 4 August 2016, 12
September 2016 (EURL-GMFF), 06 February 2017, 15 May 2017, 28 September 2017 and 23 November
2017, respectively. The applicant also spontaneously submitted additional sequencing information on
15 May 2017.
In the frame of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatics and statistical analyses, respectively.
As provided by the EFSA’s Catalogue of services, a clariﬁcation teleconference between EFSA and
the applicant took place on 11 April 2017.
In giving its scientiﬁc opinion on maize 4114 to the European Commission, Member States and the
applicant, and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has
endeavoured to respect a time limit of 6 months from the acknowledgement of the valid application.
As additional information was requested by the GMO Panel, the time limit of 6 months was extended
accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this Scientiﬁc Opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1 Dossier Part II – Section 1.2.2.1.
2 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
3 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2014-00850
4 Regulation (EU) No 503/2013 of 3 April 2013 on application for authorisation of genetically modiﬁed food and feed in
accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and amending Commission
Regulations (EC) No 604/2004 and (EC) No 1981/2006.
5 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
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1.2. Term of References as provided by the requestor
The GMO Panel was requested to carry out a scientiﬁc risk assessment of maize 4114 for food and
feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation (EC)
No 1829/2003.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of GMOs or food/feed
containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment
and/or geographical areas should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of
Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2. Data and methodologies
2.1. Data
In delivering its Scientiﬁc Opinion, the GMO Panel took into account application EFSA-GMO-NL-
2014-123, additional information provided by the applicant, scientiﬁc comments submitted by the
Member States and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of maize 4114 for food and feed uses,
import and processing in accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003.
The GMO Panel took into account Regulation (EU) No 503/2013 and the appropriate principles
described in its guidelines for the risk assessment of GM plants and derived food and feed (EFSA GMO
Panel, 2011a), the environmental risk assessment (ERA) of GM plants (EFSA GMO Panel, 2010a) and
the post-market environmental monitoring (PMEM) of GM plants (EFSA GMO Panel, 2011b).
The GMO Panel took into account the criteria included in the ‘Explanatory statement for the
applicability of the Guidance of the EFSA Scientiﬁc Committee on conducting repeated-dose 90-day
oral toxicity study in rodents on whole food/feed for GMO risk assessment’ (EFSA 2014), to perform
the assessment of the 90-day feeding study provided.
The GMO Panel assessed the applicant’s systematic literature searches in accordance with the
guidelines on literature search given in EFSA (2010) for the initial search, and in EFSA (2017) for the
latest update.
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion6 and
were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Systematic literature review7
The GMO Panel assessed the systematic literature searches provided by the applicant on
maize 4114 according to the guidelines given in EFSA (2010, 2017).
A systematic literature review as referred to in Regulation EU No 503/2013 has not been provided
in support of the risk assessment of application EFSA-GMO-NL-2014-123, because of the limited
number of relevant publications available on maize 4114.
Although the overall quality of the performed literature searches is acceptable, the GMO
Panel considers that the searches on maize 4114 could be improved. The GMO Panel, therefore,
recommends the applicant to: use truncation consistently; adapt the search for each database used,
particularly in relation to using database-speciﬁc subject headings when available (in addition to text
6 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2014-00850
7 Dossier: Part II— Section 7; Additional information: 12/4/2016 and 28/09/2017.
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words); and report the number of publications retrieved for each single subsearch performed (or
search lines).
The GMO Panel considered the relevant publications retrieved through the literature searches and
their implications for risk assessment, and addressed those in the related sections below, as
appropriate.
3.2. Molecular characterisation
3.2.1. Transformation process and vector constructs8
Maize 4114 was developed by Agrobacterium tumefaciens (also known as Rhizobium radiobacter)
mediated transformation. Immature embryos of maize line PHWWE were inoculated with the
A. tumefaciens strain LBA4404 containing the PHP27118 transformation vector.
The PHP27118 transformation vector includes one T-DNA, which contains three expression
cassettes conferring insect resistance and one expression cassette conferring herbicide tolerance. The
genetic elements of each expression cassette are depicted below:
• cry1F expression cassette: the promoter, the 50 untranslated region and the intron region of
the polyubiquitin (ubiZM1) gene from Zea mays; the codon-optimised truncated cry1F coding
sequence from Bacillus thuringiensis var. aizawai; and the terminator sequence from the
A. tumefaciens pTi15955 ORF25.
• cry34Ab1 expression cassette: the promoter, the 50 untranslated region and the intron region
of the ubiZM1 gene from Zea mays; the codon-optimised cry34Ab1 coding sequence from
B. thuringiensis strain PS149B1; and the terminator region of the proteinase inhibitor II (pinII)
gene from Solanum tuberosum.
• cry35Ab1 expression cassette: the promoter and leader sequence from a Triticum aestivum
peroxidase gene; the codon-optimised cry35Ab1 coding sequence from B. thuringiensis strain
PS149B1; and the terminator region of the pinII gene from S. tuberosum.
• pat expression cassette: the 35S promoter from Cauliﬂower Mosaic Virus (CaMV), the codon-
optimised pat coding sequence from Streptomyces viridochromogenes; and the 35S terminator
from CaMV.
The vector backbone contained elements necessary for the maintenance and selection of the
plasmid in bacteria.
3.2.2. Transgene constructs in the GM plant9
Molecular characterisation of maize 4114 was performed by Southern analysis, polymerase chain
reaction (PCR) and DNA sequence analysis, in order to determine insert copy number, size and
organisation of the inserted sequences and to conﬁrm the absence of plasmid backbone sequences.
The approach used was acceptable both in terms of coverage and sensitivity.
Southern analyses indicated that maize 4114 contains a single insert consisting of a single copy of
the T-DNA in the same conﬁguration as in the PHP27118 transformation vector. The insert and copy
number were conﬁrmed by the hybridisation signals generated with two restriction enzymes, together
with 11 probes covering the T-DNA region. The absence of vector backbone sequences was tested by
Southern analysis, using one restriction enzyme with 45 backbone-speciﬁc probes.
The nucleotide sequence of the entire insert of maize 4114 together with approximately 2 kb of
both 50 and 30 ﬂanking regions (2,398 and 2,405 bp, respectively) of maize 4114 were determined.
The results were in line with those shown by the Southern blot analyses. The insert of 11,949 bp is
identical to the T-DNA of PHP27118 transformation vector, except for the following changes: a 29 bp
deletion in the right border and a 24 bp deletion in the left border. In addition, a 24 bp insertion
composed of 15 bp of a T-DNA polylinker region and 9 bp internal sequence of cry1F gene is present
at the 50 end of the inserted T-DNA (nucleotides 1–24).
The possible interruption of known endogenous maize genes by the insertion in maize 4114 was
evaluated by bioinformatic analyses of the preinsertion locus and of the genomic sequences ﬂanking
the insert.10 BLASTn search against EST database and BLASTx search against the protein database
8 Dossier: Part II – Section 1.2.1.2.
9 Dossier: Part II – Section 1.2.2.2; Additional information 15/12/2015.
10 Dossier: Part II – Section 1.2.2.1; Additional information 28/9/2017.
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revealed signiﬁcant similarities to a hypothetical glutaredoxin-like (GRX-like) protein sequence in the 50
ﬂanking genomic region. The insertion site is located in the upstream region of the hypothetical gene.
Therefore, the insertion is unlikely to have interrupted the coding sequence of the hypothetical GRX-
like protein.
The expression of this predicted gene in leaves and developing seeds of wild type plants analysis
was not detected by northern analysis. However, even if the insertion would have altered the
expression of this predicted gene, there are no indications from comparative agronomic-phenotypic
performance and compositional analyses of any unintended effect caused by the insertion.
The results of segregation analysis (see Section 3.2.5) conﬁrmed the presence of a single insert
located in the nuclear genome.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed Cry1F,
Cry34Ab1, Cry35Ab1 and PAT proteins revealed no signiﬁcant similarities to known toxins and
allergens.10 In addition, updated bioinformatics analyses of the newly created open reading frames
(ORFs) within the insert and spanning the junctions between the insert and genomic DNA did not
indicate signiﬁcant similarities to toxins and allergens.10
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis to microbial DNA for event 4114.10 The
likelihood and potential consequences of plant-to-bacteria gene transfer are described in
Section 3.5.1.2.
3.2.3. Protein characterisation and equivalence11
Maize 4114 expresses four new proteins: a truncated version of the Cry1F protein and full-length
Cry34Ab1, Cry35Ab1 and PAT proteins. The GMO Panel has previously assessed these proteins (EFSA,
2005, 2007, 2009a).
Western blot analysis was employed to demonstrate the equivalence between Cry1F, Cry34Ab1,
Cry35Ab1 and PAT, produced in maize 4114 with plant-derived proteins in previously assessed maize
events 1507, 59122 and 1507 9 59122 as well as their corresponding Escherichia coli-produced
proteins. These data showed that they all migrated close to their expected molecular weight of ~ 68.2
kDa, ~ 13.6 kDa, ~ 43.8 kDa and ~ 20.6 kDa for truncated-Cry1F, Cry34Ab1, Cry35Ab1 and PAT,
respectively, and were comparably immunoreactive to protein speciﬁc antibodies.
3.2.4. Information on the expression of the insert12
Protein levels of Cry1F, Cry34Ab1, Cry35Ab1 and PAT proteins were analysed by enzyme-linked
immunosorbent assay (ELISA) in material harvested from replicated ﬁeld trials across eight locations in
the USA during the 2011 (six ﬁeld sites) and 2012 (two ﬁeld sites) growing seasons. Samples analysed
included leafs (V6, V9, R1, R4 and R6), roots (V6, V9, R1, R4 and R6), whole plant (V9, R1 and R6),
stalk (R1), forage (R4), grain (R6) and pollen (R1) from both not-treated and treated with glufosinate.
The mean values, standard deviations and ranges of protein expression levels in grains and forage of
the Cry1F, Cry31Ab1, Cry35Ab1 and PAT proteins are summarised in Tables 1 and 2.
Table 1: Means, standard deviations and ranges of protein levels in grains (n = 22) and forage (n = 24)
(lg/g dry weight) from maize 4114 in ﬁeld trials performed in 2011
Not-treated Treated
Grain
Cry1F 3.0(a)  1.0(b)
(1.8–5.7)(c)
3.1  1.0
(1.3–4.8)
Cry34Ab1 35.0  10.0
(17.0–51.0)
36.0  14.0
(17.0–69.0)
Cry35Ab1 0.94  0.49
(0.45–2.9)
1.0  0.41
(0.3–1.9)
PAT ˂ 0.069 (LLOQ) ˂ 0.069 (LLOQ)
11 Dossier: Part II – Section 1.2.2.1; Annex 3_PHI-2013-215.
12 Dossier: Part II – Section 1.2.2.3.
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3.2.5. Inheritance and stability of inserted DNA13
Genetic stability of the maize 4114 insert was assessed by PCR analysis of genomic DNA from ﬁve
different generations. The PCR analyses were speciﬁc for event 4114 and for the cry1F, cry34Ab1,
cry35Ab1 and pat genes, respectively. The obtained data were sufﬁcient to conclude that all the plants
tested retained the single copy of the insert, which was stably inherited in subsequent generations.
Phenotypic stability was observed by segregation analysis of the herbicide tolerance trait in plants
from ﬁve generations of maize 4114. The results supported the presence of a single insertion,
segregating in a Mendelian fashion.
3.2.6. Conclusion on molecular characterisation
The molecular characterisation data establish that maize 4114 contains a single insert consisting of
one copy of the cry1F, cry34Ab1, cry35Ab1 and pat expression cassettes. Bioinformatic analyses of the
sequences encoding the newly expressed proteins and other ORFs present within the insert, or
Not-treated Treated
Forage
Cry1F 11.0  2.9
(7.6–18.0)
11.0  3.0
(7.0–18.0)
Cry34Ab1 110.0  26.0
(54.0–160.0)
110.0  24.0
(68.0–150.0)
Cry35Ab1 20.0  4.8
(12.0–32.0)
19.0  3.5
(12.0–28.0)
PAT 2.0  0.60
(1.0–3.2)
2.0  0.67
(0.92–3.0)
LLOQ: Lower limit of quantiﬁcation.
(a): Mean.
(b): Standard deviation.
(c): Range.
Table 2: Means, standard deviations and ranges of protein levels in grains (n = 8) and forage (n = 8)
(lg/g dry weight) from maize 4114 in ﬁeld trials performed in 2012
Not-treated Treated
Grain
Cry1F 1.8(a)  0.51(b)
(0.81–2.4)(c)
2.2  0.49
(1.6–3.0)
Cry34Ab1 49.0  14.0
(22.0–63.0)
51.0  13.0
(36.0–75.0)
Cry35Ab1 0.52  0.25
(0.14–0.81)
0.68  0.33
(0.29–1.2)
PAT ˂ 0.069 (LLOQ) ˂ 0.069 (LLOQ)
Forage
Cry1F 7.3  0.86
(6.0–8.4)
8.0  1.1
(6.4–9.8)
Cry34Ab1 88  16
(66–120)
78  8.6
(60–88)
Cry35Ab1 15  3.7
(9.6–20.0)
15  3.7
(10.0–20.0)
PAT 1.9  0.56
(1.1–2.8)
2.1  0.78
(1.0–3.2)
LLOQ: Lower limit of quantiﬁcation.
(a): Mean.
(b): Standard deviation.
(c): Range.
13 Dossier: Part II – Section 1.2.2.4 and Annex 11.
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spanning the junctions between the insert and genomic DNA, did not indicate signiﬁcant similarities to
known toxins and allergens. The stability of the inserted DNA and of the introduced herbicide tolerance
trait was conﬁrmed over several generations. The Cry1F, Cry34Ab1, Cry35Ab1 and PAT proteins were
expressed and the methodology used to quantify their levels was considered adequate. The protein
characterisation data comparing Cry1F, Cry34Ab1, Cry35Ab1 and PAT produced in maize 4114 with
plant-derived proteins in previously assessed maize events 1507, 59122 and 1507 9 59122 as well as
with the corresponding E. coli-produced proteins indicate that these proteins are equivalent.
3.3. Comparative analysis
3.3.1. Choice of comparator and production of materials for the comparative
assessment14
Application EFSA-GMO-NL-2014-123 presents data on agronomic and phenotypic characteristics as
well as on forage and grain composition of maize 4114 derived from ﬁeld trials performed in the US
and Canada, and from a seed germination study performed under environmentally controlled
conditions (Table 3).
The ﬁeld trials were conducted in major maize growing areas of the US and Canada,15 representing
regions of diverse agronomic practices and environmental conditions. At each site, the following
materials were grown in a randomised complete block design with four replicates: maize 4114 not
treated with the intended herbicide (maize 4114/not-treated), maize 4114 treated with glufosinate
(maize 4114/treated), a non-GM comparator, and several commercial non-GM maize reference varieties
(i.e. three in the 2011/2012 study and four in the 2014 study). All materials were treated (sprayed)
with required maintenance pesticides (including conventional herbicides) according to local
requirements. In total, 12 and 20 non-GM maize reference varieties were included across the ﬁeld trial
sites performed in 2011/2012 and 2014, respectively.16
Maize 4114 was introgressed via backcrossing into different inbred lines (Table 3). At each site/
study, the non-GM comparator had a genetic background similar to the maize 4114 hybrid used, as
documented by the pedigree. The GMO Panel considered the selected non-GM comparator to be
suitable.
Table 3: Overview of comparative analysis studies with maize 4114 provided in application EFSA-
GMO-NL-2014-123
Study focus Study details Comparator
Commercial non-GM
reference varieties(a)
Agronomic and
phenotypic
characteristics
Field trials, 2011/2012,
USA and Canada (10 sites)(b)
PH705 9 PHW2Z(c)
PH12SG 9 PHW2Z(d)
12
Field trials, 2014, USA, (eight sites) PHR1J 9 PHW2Z 20
Seed germination study, controlled
conditions (three temperature regimes)
PHTFE 9 PHNAR 2
Compositional
analysis
Field trials, 2011/2012,
study, USA and Canada (ten sites)(b)
PH705 9 PHW2Z(c)
PH12SG 9 PHW2Z(d)
12
GM: Genetically modiﬁed.
(a): Three and four different reference varieties were grown at each site in the ﬁeld studies conducted in 2011–2012 and 2014,
respectively.
(b): Agronomic, phenotypic and compositional data were obtained from the same study.
(c): Used in the 2011 ﬁeld trials.
(d): Used in the 2012 ﬁeld trials.
14 Dossier: Part II – Section 1.3.1 and 1.3.2; Additional information: 23/9/2015.
15 The sites for the ﬁeld trials conducted in 2011 and 2012 were in Bagley (IA, USA, 2012), Bradford (IL, USA, 2011), Branchton
(ON, Canada, 2012), Carlyle (IL, USA, 2011 and 2012), Hinton (OK, USA, 2011), Jefferson (IA, USA, 2011), Wall (TX, USA,
2011), York (NE, USA, 2011 and 2012). The sites for the ﬁeld trials conducted in 2014 were in Geneva (MN, USA),
Germansville (PA, USA), Jefferson (IA, USA), Larned (KS, USA), Lebanon (IN, USA), Speer (IL, USA), Stewardson (IL, USA),
York (NE, USA).
16 The varieties used in the ﬁeld trials conducted in 2011 and 2012 were 35T06, 35T36, P0751, 36B08, Po537, 34K77, X03A115,
X7N790, X03A194, X1069G, X6M501, and X7K512. The varieties used in the ﬁeld trials conducted in 2014 were 36K67, P0423,
35T06, 35F38, XL5246, 35K02, 34N61, XL5354, 34Y02, 34B39, P0965, XL5435, 34F06, 34H31, XL6077, P1184, XL6272,
XL6175, P1319 and P1395.
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3.3.2. Statistical analysis of ﬁeld trial data
The statistical analysis of agronomic, phenotypic and compositional data from the ﬁeld trials followed
the recommendations of the GMO Panel (EFSA GMO Panel, 2010b, 2011a) and complied with Regulation
(EU) No 503/2013. This included, for each of the two treatments of maize 4114, the application of a
difference test (between the GM maize and its non-GM comparator) and an equivalence test (between
the GM maize and the set of non-GM maize reference varieties). The results of the equivalence test are
categorised into four possible outcomes (I–IV, ranging from equivalence to non-equivalence).17
Here, and in the rest of this scientiﬁc opinion, the term ‘non-GM comparator’ is used to refer to all
genetic backgrounds (PH705 9 PHW2Z, PH12SG 9 PHW2Z, PHR1J 9 PHW2Z, PHTFE 9 PHNAR,
Table 1) used in the comparative assessment studies with maize 4114.
3.3.3. Agronomic and phenotypic characteristics18
3.3.3.1. Agronomic and phenotypic characteristics tested under ﬁeld conditions
Fourteen and 15 agronomic and phenotypic end points were analysed in total in the 2011/2012 and
2014 ﬁeld trials, respectively.19 Of those, ‘pollen viability – colour and shape at 120 min’, ‘insect
damage’, ‘stalk lodging’ and ‘root lodging’ measured in the 2014 ﬁeld trials were not analysed with
formal statistical tests because of high discreteness and lack of variability in the data.
The outcome of the test of difference and test of equivalence is listed below:
• For maize 4114/not-treated, the test of difference identiﬁed statistically signiﬁcant differences
for ‘early population’, ‘time to silking’, ‘pollen viability – shape at 120 min and pollen colour at
30 and 120 min’, ‘plant height’, ‘ear height’, ‘insect damage’, ‘root lodging’ and ‘ﬁnal population’
in the 2011/2012 ﬁeld trials, and for, ‘ear height’, in the 2014 ﬁeld trials, all falling under
equivalence category I (full equivalence).
• For maize 4114/treated, the test of difference identiﬁed statistically signiﬁcant differences for
‘early population’, ‘plant height’, ‘ear height’, ‘insect damage’, ‘root lodging’, and ‘ﬁnal population’
in the 2011/2012 ﬁeld trials, and for ‘pollen viability – colour at 60 min’, ‘stay green’ and ‘yield’ in
the 2014 ﬁeld trials; all falling under equivalence category I (full equivalence), except ‘pollen
viability – colour at 60 min’ for which the test of equivalence could not be applied.
Signiﬁcant differences between maize 4114 and the non-GM comparator were not consistently
observed across the different genetic backgrounds that were used in the various sites.
The average values for the end points that were not statistically analysed fell within the range of
the non-GM reference varieties.
3.3.3.2. Agronomic and phenotypic characteristics tested under controlled conditions
The applicant reported data on seed characteristics of maize 4114. Seed germination of maize 4114
was compared with that of its non-GM comparator. Seeds were incubated under controlled conditions
at three different temperature regimes and the numbers of germinated (normal and abnormal) and
non-germinated (hard, imbibed and dead) seeds were counted. No statistically signiﬁcant differences
between maize 4114 and its non-GM comparator were observed at any temperature regime.
3.3.4. Compositional analysis
Maize 4114 grains and forage harvested from the ﬁeld trials in North America in 2011/2012
(Table 4) were analysed for 84 constituents (9 in forage and 75 in grain). The analysis included the
key constituents recommended by OECD (OECD, 2002). For 13 grain constituents,20 more than half of
the observations were below the limit of quantiﬁcation.
17 The results of the equivalence test are categorised into four possible outcomes: category I (indicating full equivalence to the
non-GM reference varieties); category II (equivalence is more likely than non-equivalence); category III (non-equivalence is
more likely than equivalence); and category IV (indicating non-equivalence).
18 Dossier: Part II – Sections 1.2.3.1 and 1.3.5; additional information: 23/9/2015 and 24/8/2016.
19 Early population (count), seedling vigour (1–9 scale), time to silking (accumulated heat units), time to pollen shed
(accumulated heat units), pollen viability (shape (% of pollen with collapsed walls) and colour (% of pollen yellow in colour) at
0, 30, 60 and 120 min), plant height (cm), ear height (cm), stay green (1–9 scale), disease incidence (1–9 scale), insect
damage (1–9 scale), stalk lodging (%), root lodging (%), ﬁnal population (count) and yield (ton/ha). The ﬁeld trials conducted
in 2014 included the end point ‘yield’ as requested by the GMO Panel.
20 Caprylic acid (C8:0), lauric acid (C12:0), myristic acid (C14:0), heptadecenoic acid (C17:1), heptadecadienoic acid (C17:2),
nonadecanoic acid (C19:0), eicosadienoic acid (C20:2), heneicosanoic acid (C21:0), tricosanoic acid (C23:0), vitamin B2
(riboﬂavin), b-tocopherol, d-tocopherol and furfural.
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The statistical analysis was applied to the remaining 71 constituents (9 in forage21 and 62 in grain22);
a summary of the outcome of the test of difference and the test of equivalence is presented in Table 4:
• For maize 4114/not-treated, all the 27 end points in grain with signiﬁcant differences with its
non-GM comparator fell under equivalence category I or II as also observed for two end points
in forage.
• For maize 4114/treated, all the 33 endpoints in grain with signiﬁcant differences with its non-
GM comparator fell under equivalence category I or II as also observed for three end points in
forage.
The GMO Panel assessed all signiﬁcant differences between maize 4114 and its non-GM
comparator, taking into account potential impact on plant metabolism and the natural variability
observed for the set of non-GM commercial reference varieties. No endpoints showing signiﬁcant
differences between maize 4114 and its non-GM comparator and falling under category III/IV were
identiﬁed.
Table 4: Outcome of the comparative compositional analysis in grains and forage for maize 4114.
The table shows the number of end points in each category
Test of difference(a)
Not-treated(c) Treated(c)
Not different
Signiﬁcantly
different
Not different
Signiﬁcantly
different
Test of equivalence(b)
Category I/II 39 29(d) 32 36(d)
Category III/IV – – – –
Not categorised 1(e) 2(f) 2(e) 1(f)
Total end points 71 71
(a): Comparison between maize 4114 and its non-GM comparator.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated/not-treated with intended herbicide: glufosinate (see Section 3.3.1).
(d): End points with signiﬁcant differences between maize 4114 and its non-GM comparator falling in equivalence category I-II
(treated and not-treated).For grains, both treated and not-treated: moisture, crude protein, ash, carbohydrates (only
treated), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), arachidic acid (C20:0), eicosenoic acid (C20:1),
behenic acid (C22:0), isoleucine, leucine, lysine, serine, c-tocopherol, total tocopherol, inositol and phytic acid. Only treated:
lignoceric acid (C24:0), alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, methionine, phenylalanine, proline,
threonine, tyrosine, valine, b-carotene and a-tocopherol. Not-treated: ADF, manganese, phosphorus, magnesium,
potassium, vitamin B6 (pyridoxine), vitamin B9 (folic acid), ferulic acid.For forage, both treated and not-treated: crude fat
and phosphorus. Only treated: carbohydrates.
(e): End points not categorised for equivalence and with signiﬁcant differences between maize 4114 and its non-GM comparator:
pantothenic acid (in grains of treated) and pantothenic acid and trypsin inhibitors (in grains of not-treated).
(f): End points not categorised for equivalence and with no signiﬁcant differences between maize 4114 and its non-GM
comparator: sodium and trypsin inhibitor (in grains of treated maize) and sodium (in grains of not-treated maize).
21 Crude protein, crude fat, crude ﬁbre, acid detergent ﬁbre (ADF), neutral detergent ﬁbre (NDF), ash, carbohydrates, calcium
and phosphorus.
22 Proximates and ﬁbre content (moisture, crude protein, crude fat, crude ﬁbre, ADF, NDF, ash and carbohydrates), amino acids
(alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine,
proline, serine, threonine, tryptophan, tyrosine and valine), fatty acids (palmitic acid (C16:0), palmitoleic acid (C16:1),
heptadecanoic acid (C17:0), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), (9,15) isomer of linoleic acid
(C18:2), linolenic acid (C18:3), arachidic acid (C20:0), eicosenoic acid (C20:1), behenic acid (C22:0), lignoceric acid (C24:0),
minerals (calcium, manganese, phosphorus, iron, magnesium, copper, potassium, sodium and zinc), vitamins (b-carotene,
vitamin B1 (thiamine), vitamin B3 (niacin), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B9 (folic acid), a-
tocopherol, c-tocopherol and total tocopherol) and other compounds (p-coumaric acid, inositol, ferulic acid, phytic acid,
rafﬁnose and trypsin inhibitors).
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3.3.5. Conclusion on comparative analysis
The GMO Panel concludes that all the compositional, agronomic and phenotypic changes identiﬁed
with respect to the non-GM comparator and the non-GM commercial reference varieties do not need
further assessment regarding food and feed safety and their environmental impact.
3.4. Food/feed safety assessment
3.4.1. Effects of processing
Based on the outcome of the comparative assessment (Section 3.3.5), processing of maize 4114
into food and feed products is not expected to result in products different from those of commercial
non-GM maize varieties.
3.4.2. Inﬂuence of temperature and pH on newly expressed proteins
Effects of temperature and pH on Cry1F, Cry34Ab1, Cry35Ab1 and PAT proteins have been
previously evaluated by the EFSA GMO Panel (EFSA, 2005, 2007, 2009a). No new studies were
provided in the context of this application.
3.4.3. Toxicology
3.4.3.1. Testing of newly expressed proteins
Maize 4114 expresses four new proteins (Cry1F, Cry34Ab1, Cry35Ab1, and PAT) previously assessed
by the GMO Panel (EFSA, 2005, 2007, 2009a). Western blot analysis demonstrated the equivalence
between these proteins produced in maize 4114 with plant-derived Cry1F, Cry34Ab1, Cry35Ab1 and
PAT proteins expressed in previously assessed maize events 1507, 59122 and 1507 9 59122 as well as
their corresponding E. coli-produced proteins (Section 3.2.3). The GMO Panel accepts that the previous
assessment of these proteins can be used for those newly expressed in maize 4114.
No safety concerns for humans and animals were identiﬁed for the Cry1F, Cry34Ab1, Cry35Ab1, and
PAT proteins previously assessed by the GMO Panel (EFSA, 2005, 2007, 2009a). Updated
bioinformatics analysis did not reveal similarities of the four proteins to known toxins. The applicant
did not provide new studies on Cry1F, Cry34Ab1, Cry35Ab1 and PAT proteins. The GMO Panel is not
aware of any new information that would change previous assessments. Based on known biological
properties, no interactions between the four proteins newly expressed in maize 4114 which could raise
safety concerns for food and feed are expected. The GMO Panel concludes that the Cry1F, Cry34Ab1,
Cry35Ab1 and PAT proteins do not raise toxicological concerns.
3.4.3.2. Testing of new constituents other than newly expressed proteins
Based on the outcome of the studies considered in the comparative analysis and molecular
characterisation, no new constituents other than newly expressed proteins have been identiﬁed in seed
and forage from maize 4114. Therefore, no further food and feed safety assessment of components
other than the newly expressed proteins is required.
3.4.3.3. Information on altered levels of food and feed constituents
None of the differences identiﬁed in seed and forage composition between maize 4114 and its non-
GM comparator required further assessment.
3.4.3.4. Testing of the whole genetically modiﬁed food and feed
No substantial modiﬁcations in the composition of maize 4114, no indication of possible unintended
effects and no indication of interactions relevant for food/feed safety were identiﬁed. Therefore, animal
studies on food/feed derived from maize 4114 are not necessary (EFSA GMO Panel, 2011a). In
accordance to Regulation (EU) No 503/2013, the applicant provided a 90-day oral repeated-dose
toxicity study on whole food and feed from maize 4114 in rats. Animal feeding studies in broiler and
channel catﬁsh fed diets containing maize 4114 material were also provided in compliance with
Regulation (EU) No 503/2013. All these studies were evaluated by the GMO Panel.
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90-day feeding studies in rats23
Singly housed Crl:CD(SD) rats (12/sex per group) were allocated to six groups using a
computerised, stratiﬁed randomisation on the basis of the group body weight mean within a sex.24
Groups were fed test, control or reference diets containing approximately 32% milled maize grain from
event 4114 either unsprayed (4114) or sprayed (4114 glufosinate (GLU)) with glufosinate (test items),
or from an appropriate non-GM comparator (control item) or one of the three non-GM commercial
varieties 32D78, 33N29 and 34P88 (reference items), respectively. The study provided was adapted
from OECD TG 408 and complying with the principles of Good Laboratory Practice (GLP).
Event-speciﬁc PCR analysis on grains prior to processing into meal conﬁrmed the molecular identity
of maize 4114. The maize 4114 event was not detected by PCR in the non-GM comparator and
commercial varieties. This was furthermore conﬁrmed by ELISA analyses in grains used to determine
the presence or absence of newly expressed proteins (Cry1F, Cry34Ab1, Cry35Ab1 and PAT). All six
maize grain lots were characterised for proximates, amino acids, minerals, vitamins, secondary
metabolites and antinutrients, pesticide residues and mycotoxins.
Balanced diets were prepared according to the speciﬁcations for PMI Certiﬁed Rodent LabDiet
#5002, with maize-milled grains inclusion rate of 32% (w/w). Event-speciﬁc PCR and ELISA analyses
conﬁrmed that event 4114 was present only in the test diets. Homogeneity and short- and long-term
stability of the test diets were considered adequate by ELISA determination of newly expressed
proteins (Cry1F, Cry34Ab1, Cry35Ab1 and PAT).
Feed and water were provided ad libitum. Animals were checked twice daily for mortality and
clinical signs. Detailed physical examinations were conducted weekly on all animals during the dosing
period. Individual body weights were recorded pretreatment and then weekly during the dosing
period. Final fasting body weights were recorded on the day of the scheduled necropsy. Feed
consumption was determined weekly during the study. Ophthalmoscopy, functional observation battery
and locomotor activity were recorded on all animals pretreatment and at the end of the study. Clinical
pathology (i.e. haematology, clinical chemistry and coagulation, urine analyses) and necropsy
examination with organs weighing were conducted at the end of the treatment period on all animals.
The animals were fasted overnight prior to blood collection while in metabolism cages for urine
collection. Organs and tissues from all sacriﬁced animals fed the test (4114 and 4114 GLU) and control
(non-GM comparator) diets and from a female (animal no. 454) fed the reference diet 32D78,
euthanised prior to the scheduled sacriﬁce for humane reasons were subjected to histopathological
examination. Kidneys and gross lesions were also histopathologically examined in all animals. Upon
completion of the histopathologic assessment, a histopathology peer review was conducted on
selected animals and organs. Due to ﬁndings observed in the kidneys in this study, a pathology
working group reviewed kidney slides from males fed the control and test (4114 and 4114 GLU) diets.
Mean and standard deviation were reported for all continuous end points for each group. In
response to a request from EFSA,25 for each end point showing statistical differences between the test
and control group, the standardised effect size (SES) and associated 95% conﬁdence interval were
provided. Furthermore, for each gender, the applicant performed a power analysis for selected
endpoints26 using prespeciﬁed effect sizes deﬁned on the basis of variance estimates and historical
control data. For all end points, except ﬁnal body weight and cumulative body weight gain, the power
estimates were at least 80%.
The main statistical analysis compared rats consuming the two test diets (4114 and 4114 GLU) with
those consuming the control diet. Individual animal was considered the experimental unit. The in-life
and terminal body weights/gain, organ weights, feed consumption/efﬁciency and clinical pathology
parameters were checked for homogeneity and normality27 and analysed with either parametric
ANOVA or non-parametric test (Dunn’s test), as appropriate. Finally, incidence of functional
observational battery (FOB) data was analysed with Fisher’s exact test using a multiple comparisons
correction (i.e. Bonferroni–Holm correction).
23 Dossier: Part II – Section 1.4.4.1 (studies PHI-2011-055 and PHI-2013-232).
24 On the basis of no statistically signiﬁcant differences among groups identiﬁed.
25 Additional information 6/2/2017 and 15/5/2017.
26 Twelve end points were selected based on their likelihood to be impacted by altered test substance palatability, digestibility, or
nutrient bioavailability: Body weight (ﬁnal, non-fasted), Cumulative body weight gain, liver weight (absolute), liver weight, %
body weight, kidney weight (absolute), kidney weight (% body weight), leukocyte count (absolute), lymphocyte count
(absolute), cholesterol (CHOL), blood urea nitrogen (BUN), creatinine (CREA), alkaline phosphatase (ALKP).
27 Levene’s test for homogeneity and Shapiro–Wilk test for normality.
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No test diet-related mortality was observed during the study. One female fed the reference diet
32D78 was euthanised on day 76 for humane reasons due to an ulcerated mammary gland mass,
histologically diagnosed as a mammary gland adenocarcinoma.
Occasionally, clinical signs and ophthalmoscopy ﬁndings, compatible with the background of this
strain of rats, were observed throughout all groups with similar or low incidence. The GMO
Panel considered these ﬁndings isolated and not treatment-related.
No statistically signiﬁcant differences in mean body weights at test day 91 and in the overall mean
body weight gains calculated from test day 0 to 91, in mean daily feed consumption and in the overall
mean daily feed efﬁciency from test day 0 to 91 were observed in males and females fed test diets
(4114 and 4114 GLU), compared to the concurrent control. Statistical differences were observed at
different times in males and females in body weights and mean daily feed efﬁciency; however, the
GMO Panel considered that, in the absence of changes in the overall mean terminal body weight and
body weight gain, the differences observed were not toxicologically relevant.
No statistically signiﬁcant differences in FOB and locomotor activity parameters were observed
between animals fed the test (4114 and 4114 GLU) and control diets.
Statistically signiﬁcant higher mean haemoglobin and haematocrit values were observed in males
fed the test diet (4114), compared to concurrent controls. These ﬁndings were not associated with
changes in haematopoietic tissue histopathology (e.g. sternum bone marrow and spleen) and
therefore not considered toxicologically relevant. No statistically signiﬁcant differences in coagulation
parameters (prothrombin time (PT) and activated partial thromboplastin time (APTT)) were observed
in animals fed the test diets (4114 and 4114 GLU), compared to concurrent control. Statistically
signiﬁcant higher mean alkaline phosphatase (~ 20%) and creatinine (20%) were observed in males
fed the test diet (4114 GLU), compared to concurrent control. These ﬁndings were not associated with
changes in related end points (e.g. liver and kidney histopathology) and were not considered
toxicologically relevant. Signiﬁcant lower mean potassium (~ 7%) was observed in females fed the test
diets (4114 and 4114 GLU), compared to concurrent control. This minimal difference is not considered
to be toxicologically relevant. No statistically signiﬁcant differences in urinalysis parameters were
observed in animals fed the test diets (4114 and 4114 GLU), compared to concurrent control.
No statistically signiﬁcant differences in ﬁnal fasting body and organ weights were observed in
animals fed the test diets (4114 and 4114 GLU), compared to concurrent control, except for a lower
mean absolute (11%) and relative-to-brain (10%) weights of epididymides in males fed the test diet
(4114 GLU); these differences were not considered to be toxicologically relevant because the mean
relative-to-body weight of epididymides was not conﬁrmed to be statistically different from concurrent
control and the decrease observed was not associated with changes in related endpoints (e.g. testes
and epididymides histopathology).
The macroscopic examination performed at necropsy on all animals revealed no gross pathological
ﬁndings related to the administration of the test material in the diet. The microscopic examinations of
selected organs and tissues did not identify relevant differences in the incidence and severity of the
histopathological ﬁndings related to the administration of the test materials in the diet.
In two males fed test diet (4114) bilateral, multiple, amphophilic-vacuolar type renal tubule
adenomas and/or carcinoma associated with multifocal atypical tubule hyperplasia were diagnosed. No
evidence of tubular epithelial cytotoxicity or preneoplastic tubular epithelial changes, as is typical of
renal tubular neoplasia, was observed. Histopathological examination of the kidneys was not
performed on three samples (two kidneys from a female given the test diet (4114); one kidney from a
female given the control diet) due to a technical mistake that occurred after their weighing. The GMO
Panel considered this not to impact the interpretation of the study, considering the normal weights
measured, the absence of macroscopic appearance observed, and the sufﬁcient number of kidneys
examined.
The assessment of the renal ﬁndings was further supported by the contribution of an expert panel
of pathologists, a review of the available literature on spontaneous renal tubule tumours in young rats
and a new repeated-dose 90-day oral toxicity study with 4114 maize focused on the assessment of
kidneys.28 The neoplastic lesions were morphologically identical to speciﬁc hyperplastic and neoplastic
lesions previously reported to occur spontaneously in multiple rat strains, including Crl:CD(SD)IGS rats.
The young age of onset for the tumours in these two rats is typical of spontaneous renal tumours in
genetically susceptible rats and not characteristic of chemically induced renal tumours. Furthermore,
the spontaneous renal tubule tumours observed in the initial repeated-dose 90-day oral toxicity study
28 Dossier: Part II – Section 1.4.4.1; Additional information 23/11/2017.
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were not reproducible under equivalent study conditions, and with a larger number of animals. The
GMO Panel concluded that the observed adenomas and carcinomas and renal tubule hyperplasias are
spontaneous lesions unrelated to consumption of the test diet.
The GMO Panel noted that the applicant only tested one dose level. However, the dose tested was
close to the highest possible without inducing nutritional imbalance according to the current
knowledge, and in accordance to the limit test dose as described in OECD TG 408. This is considered
not to compromise the study.
The GMO Panel concluded that no maize 4114-related adverse effects were observed in this study
after a 90-day administration to rats of a diet formulated with 32% milled grain from maize.
42-day feeding study in broiler29
A total of 720 (360 per sex) 1-day-old chicken broilers (Ross 708) were randomly allocated to six
dietary groups with 120 chicks per treatment (12 pens per treatment, 10 birds per pen, half for each
sex) and fed-balanced diets30 containing up to 72.8%31 maize grain from event 4114, either
unsprayed (4114) or sprayed (4114 GLU) with glufosinate (test diets), or from the non-GM comparator
(control diet) or one of the three maize reference varieties 32D78, 33N29, 34P88 (reference diets).
Diets (as mash feed) and water were offered ad libitum. No signiﬁcant differences between the groups
fed test (treated with the intended herbicide or not) and control diets were observed in mortality
(about 2%), ﬁnal body weight, weight gain, feed to gain ratio and yield of prechill organs and post-
chilled carcass and cuttable part percentages, with the exception of higher breast and thigh
percentages in test groups, compared to control (tailored mixed models of analysis of variance).
The GMO Panel concludes that administration of diets containing up to 72.8% grain from maize
event 4114 to broilers did not cause adverse effects. Moreover, the measured performance end points
were similar between groups fed-balanced diets containing GM and non-GM comparator.
Channel catﬁsh study32
A total of 480 Channel catﬁsh (sex undetermined) were randomly allocated to six dietary groups
with 80 catﬁshes per treatment (four aquaria per treatment, 20 ﬁsh per aquaria) and fed-balanced
diets formulated as sinking pellets, containing 30% ground maize grain from event 4114, either
unsprayed (4114) or sprayed (4114 GLU) with glufosinate, or from the appropriate non-GM
comparator or one of the three maize commercial varieties 32D78, 33N29, 34P88. No mortality was
observed in ﬁsh fed the test diets, and no abnormal behaviour was observed between dietary groups,
during the study. There were no statistically signiﬁcant differences in overall weight gain per ﬁsh, total
diet consumption per ﬁsh or diet conversion ratio among ﬁsh fed the reference, control and test diets.
The GMO Panel concludes that administration of balanced diets containing up to 30% maize grain
4114 and 4114 GLU to Channel catﬁsh, up to 8 weeks, did not cause adverse effects. Moreover, the
measured performance end points were similar between groups fed-balanced diets containing GM and
non-GM maize grains (comparator and references).
3.4.4. Allergenicity
The strategies to assess the potential risk of allergenicity focus on the source of the recombinant
protein, on the potential of the newly expressed protein to induce sensitisation or to elicit allergic
reactions in already sensitised individuals, and on whether the genetic transformation may have
altered the allergenic properties of the modiﬁed plant.
3.4.4.1. Assessment of allergenicity of the newly expressed proteins33
A weight-of-evidence approach was followed, taking into account all of the information obtained on
the newly expressed protein, as no single piece of information or experimental method yields sufﬁcient
evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA GMO Panel, 2010c, 2011a).
The cry1F, cry34Ab1 and cry35Ab1 genes and the pat gene originate from B. thuringiensis and
S. viridochromogenes, respectively, which are not considered to be allergenic sources.
29 Dossier: Part II – Section 1.6.2. This study was not conducted in accordance with GLP requirements.
30 Starter (0–21 days), grower (22–35 days) and ﬁnisher (35–42 days) diets.
31 61.5% in starter diets; 66.3% in grower diets; 72.8% in ﬁnisher diets.
32 Additional information 12/4/2016.
33 Dossier: Part II – Section 1.5.1 and 1.5.3.
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Updated bioinformatic analyses34 of the amino acid sequences of the Cry1F, Cry34Ab1, Cry35Ab1
and PAT proteins, using the criterion of 35% identity in a sliding window of 80 amino acids, revealed
no signiﬁcant similarities to known allergens.
The EFSA GMO Panel has previously evaluated the safety of the Cry1F, Cry34Ab1, Cry35Ab1 and
PAT proteins in the context of several applications (see Section 3.4.3.1), and no concerns on
allergenicity were identiﬁed (EFSA, 2005, 2007, 2009a). The GMO Panel is not aware of any new
information that would change these conclusions.
There is no information available on the structure or function of the newly expressed Cry1F,
Cry34Ab1, Cry35Ab1 and PAT proteins that would suggest an adjuvant effect, of the individual proteins
or their simultaneous presence in maize 4114 resulting in or enhancing an eventual speciﬁc
immunoglobulin E (IgE) response to a bystander protein.
In the context of the present application, the EFSA GMO Panel considers that there are no
indications that the newly expressed Cry1F, Cry34Ab1, Cry35Ab1 and PAT proteins in maize 4114 may
be allergenic.
3.4.4.2. Assessment of allergenicity of the whole GM plant or crop35
The EFSA GMO Panel regularly reviews the available publications on food allergy to maize.
However, to date, maize has not been considered to be a common allergenic food36 (OECD, 2002).
Therefore, the EFSA GMO Panel did not request experimental data to analyse the allergen repertoire of
GM maize.
Conclusions
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see Sections 3.2, 3.3 and
3.4), the EFSA GMO Panel found no reason of concern regarding the allergenicity of food and feed
derived from maize 4114 with respect to that derived from its non-GM comparator.
3.4.5. Dietary exposure assessment to endogenous and new constituents
According to Regulation (EU) No 503/2013, the applicant provided a dietary exposure to the Cry1F,
Cry34Ab1, Cry35Ab1 and PAT proteins produced in maize 4114.
3.4.5.1. Human dietary exposure37
Acute and chronic dietary exposure to each of the four different newly expressed proteins
expressed in maize 4114 (Cry1F, Cry34Ab1, Cry35Ab1 and PAT) were provided by the applicant.
Dietary exposure was estimated across different European countries on different age classes: young
population (toddlers, other children) and adult population (adolescents, adults, elderly and very
elderly).
For the purpose of estimating dietary exposure, the highest mean protein expression levels
between two different set of ﬁeld trials performed in 2011 and 2012 (see Tables 1 and 2 in
Section 3.2.4) were used as occurrence data. Using these data, levels of the newly expressed proteins
in the consumed maize-based food commodities were calculated considering the effect of processing
based on the protein content of the processed commodities; this is considered as a conservative
approach since it was assumed that no degradation of the newly expressed proteins occurs during
processing. Since no speciﬁc consumption data were available on consumption of commodities
containing maize 4114, a conservative scenario with 100% replacement of conventional maize was
considered. Consumption data of the relevant commodities (corn bread, corn ﬂakes, corn milling
products, cornmeal porridge, corn grain, corn snacks, sweet corn and popcorn) were retrieved from
the available summary statistics of the EFSA Comprehensive European Food Consumption Database.38
The EFSA consumption database contains information on food consumption data at individual level
34 Additional information 28/9/2017.
35 Dossier: Part II – Section 1.5.2.
36 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
37 Additional information 9/3/2018.
38 https://www.efsa.europa.eu/en/applications/gmo/tools
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from the most recent national dietary surveys in different EU Member States (EFSA, 2011; Huybrechts
et al., 2011; Merten et al., 2011).
Acute dietary exposure in high consumers was estimated by summing the exposure derived from
the 95th percentile consumption for the dominant food commodity39 among consumers only and those
exposures derived from the mean consumption of the remaining food categories in the total population
(EFSA, 2015). The highest acute dietary exposure was estimated in one dietary survey from adults
(18–65 years), with estimates of 250 lg/kg bw per day for Cry34Ab1 protein, and 15 lg/kg bw per day,
4.8 lg/kg bw per day and 0.34 lg/kg bw per day for Cry1F, Cry35Ab1 and PAT, respectively. Overall,
popcorn was the main contributor to the highest acute exposure estimates among high consumers.
Chronic dietary exposure in high consumers was estimated following the same approach as for acute
dietary exposure (EFSA, 2015), but using the available summary statistics for chronic consumption.1 The
highest chronic dietary exposure was estimated in one dietary survey from toddlers (1–3 years) with
estimates of 170 lg/kg bw per day for Cry34Ab1 protein and 10 lg/kg bw per day, 3.2 lg/kg bw per day
and 0.22 lg/kg bw per day for Cry1F, Cry35Ab1 and PAT, respectively. Overall, corn snacks and popcorn
were the main contributor to the chronic exposure estimates among high consumers.
3.4.5.2. Animal dietary exposure40
Daily dietary exposure (DDE) to each of the four newly expressed proteins in maize 4114 (Cry1F,
Cry34Ab1, Cry35Ab1 and PAT) was provided by the applicant across different livestock animal species
(poultry, swine, cattle and sheep) based on estimates, as provided for the EU by OECD (OECD, 2009),
for animal body weight, daily feed intake and the inclusion rates (percentage) of maize grain and
forage/silage in animal diets. A conservative scenario with 100% replacement of the conventional
maize (grain and/or forage/silage) was considered. The highest mean protein expression levels in
maize grain and forage between two different set of ﬁeld trials performed 2011 and 2012 (see
Tables 1 and 2 in Section 3.2.4) was used as occurrence data. Among the four newly expressed
proteins, Cry34Ab1 showed the highest estimated DDE (mg/kg bw): 2.52 in broiler chickens (4114
maize grain replacement), 2.54 in dairy cattle (4114 maize forage replacement) and 3.13 in dairy
cattle (combination of 4114 maize grain and forage replacement). The highest estimated DDEs to the
other three newly expressed proteins were 0.05, 0.45 and 0.29 mg/kg body weight, respectively, for
PAT, Cry35Ab1 and Cry1F in cattle (combination of 4114 maize grain and forage replacement).
3.4.6. Nutritional assessment of GM food/feed
The intended trait of maize 4114 is insect resistance and herbicide tolerance, with no intention to
alter nutritional parameters. Comparison of the seed and forage composition of maize 4114 with the
non-GM comparator and the non-GM commercial reference varieties did not identify differences that
would require a nutritional assessment as regards food and feed (see Section 3.3.5). From these data,
the GMO Panel concludes that the nutritional impact of maize 4114-derived food and feed is expected
to be similar to that from the non-GM comparator and non-GM commercial reference varieties.
3.4.7. Post-market monitoring of GM food/feed
The food/feed products derived from maize 4114 are as safe and nutritious as those derived from
the non-GM comparator. Therefore, the GMO Panel considers that the post-market monitoring (EFSA
GMO Panel, 2011a) of the food and feed derived from maize 4114 is not necessary.
3.4.8. Conclusion on the food/feed safety assessment
The GMO Panel did not identify safety concerns regarding the toxicity and allergenicity of the proteins
Cry1F, Cry34Ab1, Cry35Ab1 and PAT produced in maize 4114 and found no evidence that the genetic
modiﬁcation might signiﬁcantly change the overall allergenicity of maize 4114. Based on the outcome of
the comparative assessment, the GMO Panel concludes that the nutritional impact of maize 4114-derived
food and feed is expected to be similar to that from the non-GM comparator and non-GM commercial
reference varieties. The GMO Panel concludes that maize 4114 is as safe and nutritious as the non-GM
comparator and the non-GM reference varieties tested.
39 Dominant food commodity refers to the food that will lead to the highest exposure among all consumed foods.
40 Dossier: Part II – Section 2.
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3.5. Environmental risk assessment and monitoring plan
Considering the scope of application EFSA-GMO-NL-2014-123, which excludes cultivation, the ERA
of maize 4114 mainly takes into account: (1) the exposure of microorganisms to recombinant DNA in
the gastrointestinal tract of animals fed GM material and microorganisms present in environments
exposed to faecal material of these animals (manure and faeces); and (2) the accidental release into
the environment of viable maize 4114 grains during transportation and/or processing (EFSA GMO
Panel, 2010a).
3.5.1. Environmental risk assessment
3.5.1.1. Persistence and invasiveness of the GM plant41
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, the absence of a dormancy phase and susceptibility to plant
pathogens, herbivores and cold climate conditions (OECD, 2003). Field observations indicate that
maize grains may survive and overwinter in some EU regions, resulting in volunteers in subsequent
crops (e.g. Gruber et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers
have been shown to grow weakly and ﬂower asynchronously with the maize crop (Palaudelmas et al.,
2009). Thus, the establishment and survival of feral and volunteer maize in the EU is currently limited
and transient.
It is unlikely that the intended traits of maize 4114 will provide a selective advantage to maize
plants, except when they are exposed to glufosinate-containing herbicides or infested by insect pests
that are susceptible to the Cry1F, Cry34Ab1 or Cry35Ab1 proteins. However, this ﬁtness advantage will
not allow the GM plant to overcome other biological and abiotic factors (described above) limiting
plant’s persistence and invasiveness. Therefore, the presence of the intended traits will not affect the
persistence and invasiveness of the GM plant.
In conclusion, the GMO Panel considers it very unlikely that maize 4114 will differ from
conventional maize hybrid varieties in its ability to survive until subsequent seasons, or to establish
occasional feral plants under European environmental conditions in case of accidental release into the
environment of viable GM maize grains.
3.5.1.2. Potential for gene transfer42
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA or through vertical gene ﬂow via cross-pollination from feral
plants originating from spilled grains.
Plant to microorganism gene transfer
Genomic DNA can be a component of food and feed products derived from maize. It is well
documented that such DNA becomes substantially degraded during processing and digestion in the
human or animal gastrointestinal tract. However, bacteria in the digestive tract of humans and
domesticated animals and in other environments may be exposed to fragments of DNA, including the
recombinant fraction of such DNA.
Current scientiﬁc knowledge of recombination processes in bacteria suggests that horizontal
transfer of non-mobile, chromosomally located DNA fragments between unrelated organisms (such as
from plants to bacteria) is not likely to occur at detectable frequencies under natural conditions (for
further details, see EFSA, 2009b).
The only mechanism known to facilitate horizontal transfer of non-mobile, chromosomal DNA
fragments to bacterial genomes is HR. This requires the presence of at least two stretches of DNA
sequences that are similar in the recombining DNA molecules. In the case of sequence identity with
the transgene itself, recombination would result in gene replacement. In the case of identity with two
or more regions ﬂanking recombinant DNA, recombination could result in the insertion of additional
DNA sequences in bacteria and thus confer the potential for new properties.
41 Dossier: Part II – Section 5.3.1.
42 Dossier: Pa rt II – Section 5.3.1 and 5.3.2.
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Maize 4114 contains genetic elements originating or derived from bacteria, i.e. (1) the truncated
cry1F gene from B. thuringiensis var. aizawai; (2) the terminator sequence from the A. tumefaciens
pTi15955 ORF25 in the cry1F cassette; (3) the codon-optimised cry34Ab1 gene from B. thuringiensis
strain PS149B1; (4) the codon-optimised cry35Ab1 gene from B. thuringiensis strain PS149B1; and (5)
the codon-optimised pat gene from S. viridochromogenes.
Bioinformatic analysis of the inserted DNA conﬁrmed that all three cry genes and the pat genes
derived from bacteria were codon-optimised and thus showed insufﬁcient DNA sequence identity to
facilitate HR with DNA from environmental bacterial genes. However, a 100% sequence identity with
bacterial DNA was found for 714 nucleotides from the ORF25 terminator which could facilitate HR.
A. tumefaciens occurs in soil, water and in the plant rhizosphere. It is therefore not expected to be
prevalent in the main receiving environments, i.e. the gastrointestinal tract of humans or animals. A
recombination within the ORF25 terminator region would only result in DNA sequence replacement and
thus not confer any novel trait or selective advantage.
In summary, given the nature of the recombinant DNA, the GMO Panel identiﬁed no safety concern
linked to an unlikely but theoretically possible HGT.
Plant to plant gene transfer
The potential for occasional feral maize 4114 plants originating from grain import spills to transfer
recombinant DNA to sexually compatible plants and the environmental consequences of this transfer
were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
ﬂowering and environmental conditions favouring cross-pollination.
Maize is predominantly an annual cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize
outside cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA,
2016; Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and
weedy Zea species, such as teosintes, and/or maize-teosinte hybrids, occurring in cultivated areas
(EFSA, 2016; Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.5.1.1). The likelihood/frequency of cross-pollination between occasional feral
GM maize plants resulting from grain spillage, and weedy or cultivated Zea species is considered
extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the opinion that
the likelihood of environmental effects as a consequence of the spread of genes from occasional feral
GM maize plants in Europe will not differ from that of conventional maize varieties for the reasons
given in Section 3.5.1.1, even in the case of treatment with the intended herbicide.
3.5.1.3. Interactions of the GM plant and target organisms43
Taking the scope of application EFSA-GMO-NL-2014-123 (no cultivation) into account, potential
interactions of occasional feral maize 4114 plants arising from grain import spills with target organisms
are not considered a relevant issue.
3.5.1.4. Interactions between the GM plant and non-target organisms44
Given that environmental exposure of non-target organisms to spilled maize 4114 grains or
occasional feral GM maize plants arising from spilled GM grains is limited, and because ingested
proteins are degraded before entering the environment through faecal material of animals fed GM
maize, potential interactions of the GM plant with non-target organisms are not considered by the
GMO Panel to raise any environmental safety concern. Interactions that may occur between the Cry
proteins will not alter this conclusion.
3.5.1.5. Interactions with the abiotic environment and biogeochemical cycles45
Given that environmental exposure to spilled grains or occasional feral maize 4114 plants arising
from grain import spills is limited, and because ingested proteins are degraded before entering the
environment through faecal material of animals fed GM maize, potential interactions of the GM plant
43 Dossier: Part II – Section 5.3.3.
44 Dossier: Part II – Section 5.3.4.
45 Dossier: Part II – Section 5.3.6.
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with the abiotic environment and biogeochemical cycles are not considered by the GMO Panel to raise
any environmental safety concern.
3.5.2. Post-market environmental monitoring46
The objectives of a PMEM, according to Annex VII of Directive 2001/18/EC, are: (1) to conﬁrm that
any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or its
use, in the ERA are correct; and (2) to identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the ERA.
Monitoring is related to risk management, and thus, a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from maize 4114, no case-
speciﬁc monitoring is required.
The PMEM plan proposed by the applicant for maize 4114 includes: (1) the description of a
monitoring approach involving operators (federations involved in import and processing), reporting to
the applicant, via a centralised system, any observed adverse effect(s) of GMOs on human health and
the environment; (2) a coordinating system established by EuropaBio for the collection of information
recorded by the various operators; and (3) the review of relevant scientiﬁc publications retrieved from
literature searches (Lecoq et al., 2007; Windels et al., 2008). The applicant proposes to submit a
PMEM report on an annual basis and a ﬁnal report at the end of the authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of maize 4114. The GMO Panel agrees with the reporting intervals proposed by
the applicant in its PMEM plan.
In the context of PMEM, the applicant should improve the literature searches according to the GMO
Panel recommendations given in Section 3.1.
3.5.3. Conclusion on the environmental risk assessment and monitoring plant
The GMO Panel concludes that it is unlikely that maize 4114 would differ from conventional maize
varieties in its ability to persist under European environmental conditions. Considering the scope of
application EFSA-GMO-NL-2014-123, interactions of occasional feral maize 4114 plants with the biotic
and abiotic environment are not considered to be relevant issues. The analysis of HGT from
maize 4114 to bacteria does not indicate a safety concern. Therefore, considering the introduced
traits, the outcome of the comparative analysis, and the routes and levels of exposure, the GMO
Panel concludes that maize 4114 would not raise safety concerns in the event of accidental release of
viable GM maize grains into the environment.
The scope of the PMEM plan provided by the applicant and the reporting intervals are in line with
the intended uses of maize 4114.
4. Conclusions
The GMO Panel was asked to carry out a scientiﬁc assessment of maize 4114 for import, processing
and food and feed uses in accordance with Regulation (EC) No 1829/2003.
The molecular characterisation data and bioinformatics analyses did not identify issues requiring
further assessment for food/feed safety.
The GMO Panel concludes that none of the differences identiﬁed in the agronomic, phenotypic and
compositional characteristics of maize 4114 required further assessment regarding environmental and
food and feed safety.
The GMO Panel did not identify safety concerns regarding the toxicity and allergenicity of the
proteins Cry1F, Cry34Ab1, Cry35Ab1 and PAT expressed in maize 4114 and found no evidence that the
genetic modiﬁcation might signiﬁcantly change the overall allergenicity of maize 4114. The nutritional
impact of maize 4114-derived food and feed is expected to be similar to that from the non-GM
comparator and non-GM commercial reference varieties.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from maize 4114 into the environment. The PMEM plan and
reporting intervals are in line with the intended uses of maize 4114.
46 Dossier: Part II – Section 6.
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Based on the relevant publications identiﬁed through the literature searches, the GMO Panel did not
identify any safety issues pertaining to the intended uses of maize 4114. In the context of PMEM, the
applicant should improve the literature searches according to the GMO Panel recommendations.
In conclusion, the GMO Panel considers that maize 4114, as described in this application, is as safe
as the non-GM comparator and other non-GM maize varieties with respect to potential effects on
human and animal health and the environment.
Documentation requested and provided to EFSA
1) Letter from the Competent Authority of the Netherlands received on 27 November 2014
concerning a request for placing on the market of genetically modiﬁed maize 4114 submitted
by Pioneer Overseas Corporation in accordance with Regulation (EC) No 1829/2003
(application reference EFSA-GMO-NL-2014-123).
2) Acknowledgement letter dated 1 December 2014 from EFSA to the Competent Authority of
the Netherlands.
3) Letter from EFSA to applicant dated 20 January 2015 requesting additional information
under completeness check.
4) Letter from applicant to EFSA received on 2 March 2015 providing additional information
under completeness check.
5) Letter from EFSA to applicant dated 30 March 2015 delivering the ‘Statement of Validity’ of
application EFSA-GMO-NL-2014-123 for placing on the market of genetically modiﬁed maize
4114 submitted by Pioneer Overseas Corporation in accordance with Regulation
(EC) No 1829/2003.
6) Email from EFSA to applicant dated 22 April 2015 requesting missing parts of the
application.
7) Email from applicant to EFSA received on 24 April 2015 providing missing parts of the
application.
8) Letter from EURL to EFSA dated 22 April 2015 requesting EFSA to stop the clock on behalf
of the EURL.
9) Letter from EFSA to applicant dated 23 April 2015 requesting additional information for
EURL and stopping the clock.
10) Email from applicant to EFSA received on 24 April 2015 providing additional information
under completeness check.
11) Letter from EFSA to applicant dated 11 May 2015 requesting additional information and
maintaining the clock stopped.
12) Letter from EFSA to applicant dated 17 July 2015 requesting additional information and
maintaining the clock stopped.
13) Letter from applicant to EFSA received on 23 September 2015 providing additional
information.
14) Letter from applicant to EFSA received on 23 September 2015 providing additional
information.
15) Letter from EFSA to applicant dated 3 December 2015 requesting additional information
and maintaining the clock stopped.
16) Letter from applicant to EFSA received on 15 December 2015 providing additional
information.
17) Letter from EFSA to applicant dated 12 February 2016 requesting additional information
and maintaining the clock stopped.
18) Letter from applicant to EFSA received on 12 April 2016 providing additional information.
19) Letter from EURL to EFSA dated 15 June 2016 requesting EFSA to re-start the clock on
behalf of the EURL.
20) Letter from EFSA to applicant dated 20 June 2016 re-starting the clock.
21) Letter from EFSA to applicant dated 29 June 2016 requesting additional information and
stopping the clock.
22) Letter from EURL to EFSA dated 15 July 2016 requesting EFSA to stop the clock on behalf
of the EURL.
23) Letter from applicant to EFSA received on 4 August 2016 providing additional information.
24) Letter from EURL to EFSA dated 14 September 2016 requesting EFSA to re-start the clock
on behalf of the EURL.
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25) Letter from EFSA to applicant dated 15 September 2016 re-starting the clock.
26) Letter from EFSA to applicant dated 5 December 2016 requesting additional information
and stopping the clock.
27) Letter from applicant to EFSA received on 6 February 2017 providing additional
information.
28) Email from EFSA to applicant dated 9 February 2017 re-starting the clock on 6 February
2017.
29) Letter from EFSA to applicant dated 14 March 2017 requesting additional information and
stopping the clock.
30) Letter from applicant to EFSA received on 15 May 2017 providing additional information.
31) Email from EFSA to applicant dated 15 May 2017 re-starting the clock.
32) Letter from applicant to EFSA received on 15 May 2017 providing sequencing information
spontaneously.
33) Letter from EFSA to applicant dated 24 May 2017 requesting additional information and
stopping the clock.
34) Letter from applicant to EFSA received on 6 July 2017 requesting an extension of the
deadline to submitted additional information requested.
35) Email from EFSA to applicant dated 17 July 2017 accepting the deadline extension demand
to submit additional information requested.
36) Letter from EFSA to applicant dated 25 September 2017 requesting additional information
and maintaining the clock stopped.
37) Letter from applicant to EFSA received on 28 September 2017 providing additional
information.
38) Letter from applicant to EFSA received on 23 November 2017 providing additional
information.
39) Email from EFSA to applicant dated 23 November 2017 re-starting the clock.
40) Letter from EFSA to applicant dated 19 January 2018 requesting additional information and
stopping the clock.
41) Letter from applicant to EFSA received on 9 March 2018 providing additional information.
42) Email from EFSA to applicant dated 3 March 2018 re-starting the clock.
43) Letter from applicant to EFSA received on 9 April 2018 regarding conﬁdentiality parts of
the application.
44) Letter from applicant to EFSA received on 24 April 2018 providing a Public Access version
of the application.
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Abbreviations
ADF acid detergent ﬁbre
ALKP alkaline phosphatase
APTT activated partial thromboplastin time
BUN blood urea nitrogen
bw body weight
CaMV Cauliﬂower Mosaic Virus
CHOL cholesterol
CREA creatinine
DDE Daily dietary exposure
ELISA enzyme-linked immunosorbent assay
GLP Good Laboratory Practice
GLU glufosinate
GMO genetically modiﬁed organism
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
GRX glutaredoxin
HGT horizontal gene transfer
HR homologous recombination
NDF neutral detergent ﬁbre
NEP newly expressed proteins
ORFs open reading frames
OECD Organisation for Economic Co-operation and Development
PAT phosphinothricin acetyltransferase
PCR polymerase chain reaction
PMEM post-market environmental monitoring
PT prothrombin time
SES standardised effect size
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